Z
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
Price:
27.33
CNY
-0.04%
Market Closed
Market Cap:
¥14.3B
Relative Value
The Relative Value of one Zhejiang Wolwo Bio-Pharmaceutical Co Ltd stock under the Base Case scenario is 19.01 CNY. Compared to the current market price of 27.33 CNY, Zhejiang Wolwo Bio-Pharmaceutical Co Ltd is Overvalued by 30%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
19.01
CNY
Overvaluation 30%
Z
Multiples Across Competitors
Competitors Multiples
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Competitors
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
Z
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SZSE:300357
|
14.3B CNY | 13.6 | 36.7 | 33.3 | 33.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
989.2B USD | 15 | 47.4 | 32 | 34 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
593.2B USD | 6.3 | 22 | 15.3 | 18.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
294.8B CHF | 4.8 | 31.3 | 13.2 | 15.4 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.1B GBP | 5.4 | 31.1 | 17.2 | 24.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
248.7B CHF | 5.7 | 22.9 | 14.1 | 18.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
310.9B USD | 4.7 | 16.7 | 10.4 | 12.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.4 | 7.7 | 9.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.8B USD | 2.5 | 19.8 | 7.4 | 9.9 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
124.9B USD | 2.6 | 17.5 | 7.3 | 9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
